Neuland Laboratories to Open $30M Commercial Peptide Manufacturing Facility in India

Neuland Laboratories, a Hyderabad-based contract development and manufacturing organization (CDMO), announced plans to open a commercial-scale peptide manufacturing facility at its 17-acre Bonthapally campus in summer 2026. The expansion, backed by approximately $30 million in customer commitments, represents one of the most significant peptide production investments in Asia this year.

Scaling to meet the GLP-1 wave

The first of four planned manufacturing modules will add 6,370 liters of peptide synthesis capacity — a substantial increase aimed squarely at the global supply crunch created by the explosive growth of GLP-1 receptor agonists. Drugs like semaglutide, a GLP-1 receptor agonist marketed by Novo Nordisk as Ozempic and Wegovy, and tirzepatide, Eli Lilly's dual GIP/GLP-1 receptor agonist sold as Mounjaro and Zepbound, have generated unprecedented demand for peptide active pharmaceutical ingredients (APIs).

The facility will feature automated solid-phase peptide synthesis, large-scale purification systems, and cGMP-compliant production lines — the infrastructure needed to serve pharmaceutical clients requiring commercial-scale peptide batches.

India's growing role in peptide supply chains

Neuland's expansion reflects a broader shift in the global peptide supply chain. India, already a powerhouse in generic pharmaceutical manufacturing, is positioning itself as a major player in the more specialized peptide CDMO market. The country offers cost advantages, a deep talent pool in chemistry and process engineering, and an established regulatory track record with the FDA and EMA.

The timing aligns with a wave of peptide manufacturing investments globally. Novo Nordisk's $12 billion manufacturing expansion and similar moves by other large pharma companies have highlighted that the peptide industry's manufacturing capacity has not kept pace with clinical and commercial demand.

What to watch

Neuland has outlined a phased expansion plan with additional modules beyond Module 1, suggesting the company expects sustained growth in peptide CDMO demand. For the peptide therapeutics industry, facilities like this are critical infrastructure — without adequate manufacturing capacity, even approved drugs face the supply shortages that have plagued the GLP-1 market over the past two years.